Imaging for Interventional Radiology Liver-Directed Therapies for Neuroendocrine Liver Metastases

Abstract

Neuroendocrine tumors are an indolent, heterogeneous group of tumors that primarily arise from the gastropancreatic tract and lungs. Most patients present with liver metastases at the time of diagnosis, which cause significant morbidity and mortality due to excess hormone secretion, bile duct obstruction, and liver damage. A small percentage of these patients are eligible for potential cure through surgical resection. However, interventional radiology provides liver-directed therapies, such as percutaneous ablation, transarterial embolization, chemoembolization, and radioembolization, for palliative care and potential bridging to debulking and surgical resection of neuroendocrine liver metastases. This article aims to provide a brief overview of these liver-directed therapies focusing on the pre-, intra-, and postprocedural imaging findings.

Keywords

neuroendocrine - liver metastases - ablation - radioembolization - chemoembolization - interventional radiology

Publication History

Article published online:
19 August 2024

• References

• 1 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021; 34 (02) 130-141
• 2 Harring TR, Nguyen NT, Goss JA, O'Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol 2011; 2011: 154541
• 3 Clift AK, Thomas R, Frilling A. Developments in interventional management of hepatic metastases from neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2023; 37 (05) 101798
• 4 Sanli Y, Garg I, Kandathil A. et al. Neuroendocrine tumor diagnosis and management: ⁶⁸Ga-DOTATE PET/CT. AJR Am J Roentgenol 2018; 211 (02) 267-277
• 5 Ezziddin S, Meyer C, Kahancova S. et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med 2012; 53 (11) 1663-1669
• 6 Galgano SJ, Iravani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of neuroendocrine neoplasms: monitoring treatment response - AJR expert panel narrative review. AJR Am J Roentgenol 2022; 218 (05) 767-780
• 7 Zener R, Yoon H, Ziv E. et al. Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes. Cardiovasc Intervent Radiol 2019; 42 (04) 569-576
• 8 Lestra T, Kanagaratnam L, Mulé S. et al. Measurement variability of liver metastases from neuroendocrine tumors on different magnetic resonance imaging sequences. Diagn Interv Imaging 2018; 99 (02) 73-81
• 9 Gulpinar B, Peker E, Kul M, Elhan AH, Haliloglu N. Liver metastases of neuroendocrine tumors: Is it possible to diagnose different histologic subtypes depending on multiphasic CT features?. Abdom Radiol (NY) 2019; 44 (06) 2147-2155
• 10 Miszczuk M, Chapiro J, Do Minh D. et al. Analysis of tumor burden as a biomarker for patient survival with neuroendocrine tumor liver metastases undergoing intra-arterial therapies: a single center retrospective analysis. Cardiovasc Intervent Radiol 2022; 45 (10) 1494-1502
• 11 Weber M, Kessler L, Schaarschmidt B. et al. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. Nucl Med Commun 2020; 41 (04) 363-369
• 12 Ambrosini V, Kunikowska J, Baudin E. et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021; 146: 56-73
• 13 Morse B, Jeong D, Thomas K, Diallo D, Strosberg JR. Magnetic resonance imaging of neuroendocrine tumor hepatic metastases: Does hepatobiliary phase imaging improve lesion conspicuity and interobserver agreement of lesion measurements?. Pancreas 2017; 46 (09) 1219-1224
• 14 Ramdhani K, Braat AJAT. The evolving role of radioembolization in the treatment of neuroendocrine liver metastases. Cancers (Basel) 2022; 14 (14) 3415
• 15 Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Contr 2006; 13 (01) 72-78
• 16 Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of radioembolization in metastatic neuroendocrine tumors. Cardiovasc Intervent Radiol 2022; 45 (11) 1590-1598
• 17 Tirumani SH, Jagannathan JP, Braschi-Amirfarzan M. et al. Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. Abdom Radiol (NY) 2018; 43 (09) 2329-2339
• 18 Gupta S, Yao JC, Ahrar K. et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9 (04) 261-267
• 19 Sahu S, Schernthaner R, Ardon R. et al. Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: Can enhancing tumor burden of the whole liver help predict patient survival?. Radiology 2017; 283 (03) 883-894
• 20 Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis. Digestion 2003; 68 (2-3): 94-101
• 21 Brown KT, Koh BY, Brody LA. et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999; 10 (04) 397-403